Thu, Dec 25, 2014, 12:27 PM EST - U.S. Markets closed for Christmas

Recent

% | $
Quotes you view appear here for quick access.

Curis, Inc. Message Board

  • biglabowski99 biglabowski99 Aug 30, 2012 10:51 PM Flag

    Roche/Genentech drug beats...

    Roche/Genentech drug beats back treatment-resistant breast cancer cells

    The drug - vismodegib - has been used to fight a form of skin cancer
    August 30, 2012 | By Mark Hollmer

    A skin cancer drug developed by Roche ($RHHBY)/Genentech appears to beat back breast cancer cells resistant to tamoxifen, a standard course of treatment, researchers from Ohio have discovered. They also figured out how those cells resistant to tamoxifen both grow and multiply.

    Bhuvaneswari Ramaswamy and Sarmila Majumder of the Ohio State University Comprehensive Cancer Center made the finding, which is detailed in the journal Cancer Research.

    It turns out that tumors in 30% of patients with estrogen-sensitive breast cancer eventually resist tamoxifen treatment. And the research team proceeded to figure out why. Those cells, it seems, depend on the hedgehog and PI3K/AKT signaling pathways for growth. But the researchers determined that the Roche/Genentech drug Erivedge (vismodegib) may be a solution. The drug, which gained regulatory approval last year as a treatment for basal cell carcinoma, blocks the hedgehog pathway, for one thing. And in animal tests, it stopped tamoxifen-resistant human breast tumors from growing.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • combo therapy with CUDC-907 and vismodegib?

      nice preclinical publication in a solid journal, first time in a while (Cancer Research, cell line and mouse data). Too bad that out of like 30 trails with vismodegib there aren't any breast cancer ones currently going on. Novartis has a Ph1 trial with their hedgehog inhibitor LDE225 being administered to some breast cancer patients as part of a more general "advanced solid tumors" trial. LDE225 is also being administered in combination with BKM120 in that trial, so it's probably not going to be very useful in gaining any clues in figuring out the effect of blocking hedgehog in some tamoxifen resistant patients (if there are any enrolled by chance)...

      the second last author on the Cancer Research article (Charles L. Shapiro) is a MD and participates in a lot of breast cancer clinical trials. Hopefully, he's motivated to try vismodegib (and talk to roche about their findings) on some of his tamoxifen-resistant patients who fail to respond to whatever therapy trial whatever is investigating...

    • Another good get, BigL, thanks!

      Sentiment: Strong Buy

    • Sounds like a big new market. Add that to BCC and maybe pancreatic? How many more prescriptions per month will that be and how soon?

      Sentiment: Strong Buy

    • whoooo-hoooo. great news, bigL :))

 
CRIS
1.29+0.04(+3.20%)Dec 24 12:59 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.